3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
60
Breast Neoplasms
21
Neoplasms
19
Fallopian Tube Neoplasms
16
Prostatic Neoplasms
15
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Endometrial Neoplasms
8
Glioblastoma
7
Triple Negative Breast Neoplasms
6
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Small Cell Lung Carcinoma
4
Glioma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Mesothelioma
3
Melanoma
3
Head and Neck Neoplasms
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Sarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Diseases
2
Mesothelioma, Malignant
2
Interventions
Temozolomide
111
Radiotherapy
60
Carboplatin
30
Bevacizumab
30
Magnetic Resonance Spectroscopy
28
Carmustine
28
Filgrastim
23
Surgical Procedures, Operative
22
Irinotecan
22
Radiation
17
Lomustine
16
Vincristine
15
Etoposide
15
Specimen Handling
13
Peripheral Blood Stem Cell Transplantation
13
O(6)-benzylguanine
13
Radiotherapy, Intensity-Modulated
12
Procarbazine
11
Erlotinib Hydrochloride
11
Cyclophosphamide
11
Chemotherapy, Adjuvant
11
sargramostim
10
Thiotepa
10
Cisplatin
10
Flucytosine
9
Everolimus
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Granulocyte Colony-Stimulating Factor
8
Vorinostat
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Astrocytoma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts